LEXINGTON — Cubist Pharmaceuticals Inc. said its profit grew 18 percent in the second quarter as sales of its antibiotic Cubicin improved.
Profit increased to $28.2 million, or 45 cents per share, from $23.8 million, or 40 cents per share. Revenue climbed 29 percent to $168.5 million from $130.8 million.
Thomson Reuters says analysts expected a profit of 42 cents per share and $160.9 million in revenue.
US sales of Cubicin rose 23 percent to $155 million. The drug is used to treat severe skin and bloodstream infections.